DEC2 Inhibitors
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SR 8278 | 1254944-66-5 | sc-473353 | 10 mg | $337.00 | ||
SR8278 is a REV-ERBα/β agonist that directly modulates DEC2 by targeting REV-ERBα and REV-ERBβ. By activating these nuclear receptors, SR8278 influences downstream signaling events that intersect with DEC2, directly impacting its function. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
Triptolide is a diterpene triepoxide that indirectly modulates DEC2 through the NF-κB signaling pathway. By inhibiting NF-κB activation, Triptolide disrupts downstream signaling cascades involving DEC2, indirectly influencing its function. This indirect modulation occurs through the interference with NF-κB-dependent regulation of DEC2, affecting its activation and the subsequent cellular responses influenced by DEC2 signaling. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D is an RNA synthesis inhibitor that indirectly modulates DEC2 through the inhibition of transcription. By preventing RNA synthesis, Actinomycin D disrupts the expression of genes associated with DEC2, indirectly influencing its function. This indirect modulation occurs through interference with the transcriptional regulation of DEC2, affecting its activation and the subsequent cellular responses influenced by DEC2 signaling. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Selumetinib is a mitogen-activated protein kinase (MEK) inhibitor that indirectly modulates DEC2 through the MAPK/ERK pathway. By inhibiting MEK, Selumetinib disrupts the downstream signaling cascades involving DEC2, indirectly influencing its function. This indirect modulation occurs through the interference with the MAPK/ERK-dependent regulation of DEC2, affecting its activation and the subsequent cellular responses influenced by DEC2 signaling. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
JQ1 is a bromodomain and extra-terminal (BET) protein inhibitor that directly influences DEC2 through the inhibition of BET proteins. By targeting BET proteins, JQ1 disrupts their interaction with chromatin associated with DEC2, directly modulating DEC2 function. This direct inhibition occurs through interference with the epigenetic regulation of DEC2, affecting its activity and the subsequent cellular responses influenced by DEC2 signaling. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $94.00 $348.00 | 69 | |
BML-275 (Dorsomorphin) is an AMP-activated protein kinase (AMPK) inhibitor that indirectly modulates DEC2 through the AMPK signaling pathway. By inhibiting AMPK, Dorsomorphin disrupts the downstream signaling cascades involving DEC2, indirectly influencing its function. This indirect modulation occurs through the interference with the AMPK-dependent regulation of DEC2, affecting its activation and the subsequent cellular responses influenced by DEC2 signaling. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $37.00 $77.00 $184.00 $510.00 $1224.00 $5814.00 | 8 | |
Niclosamide is an anthelmintic drug that indirectly modulates DEC2 through the Wnt/β-catenin pathway. By inhibiting Wnt/β-catenin signaling, Niclosamide disrupts downstream signaling cascades involving DEC2, indirectly influencing its function. This indirect modulation occurs through interference with the Wnt/β-catenin-dependent regulation of DEC2, affecting its activation and the subsequent cellular responses influenced by DEC2 signaling. | ||||||
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
GSK-J4 is a lysine-specific demethylase 1 (LSD1) inhibitor that directly modulates DEC2 by targeting the demethylase activity of LSD1. By inhibiting LSD1, GSK-J4 disrupts the demethylation of histones associated with DEC2, directly influencing DEC2 function. This direct inhibition occurs through the interference with the epigenetic regulation of DEC2, affecting its activity and the subsequent cellular responses influenced by DEC2 signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 mitogen-activated protein kinase (MAPK) inhibitor that indirectly modulates DEC2 through the p38 MAPK pathway. By inhibiting p38 MAPK, SB203580 disrupts downstream signaling cascades involving DEC2, indirectly influencing its function. This indirect modulation occurs through the interference with the p38 MAPK-dependent regulation of DEC2, affecting its activation and the subsequent cellular responses influenced by DEC2 signaling. | ||||||
(S)-HDAC-42 | 935881-37-1 | sc-296364 sc-296364A | 1 mg 5 mg | $94.00 $409.00 | ||
(S)-HDAC-42 is a histone deacetylase (HDAC) inhibitor that directly influences DEC2 through the inhibition of HDAC activity. By targeting HDAC, (S)-HDAC-42 disrupts the deacetylation of histones associated with DEC2, directly modulating DEC2 function. This direct inhibition occurs through the interference with the epigenetic regulation of DEC2, affecting its activity and the subsequent cellular responses influenced by DEC2 signaling. | ||||||